A detailed history of Thrivent Financial For Lutherans transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 9,120 shares of REGN stock, worth $6.24 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
9,120
Previous 7,814 16.71%
Holding current value
$6.24 Million
Previous $8.21 Million 16.73%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$1024.09 - $1201.76 $1.34 Million - $1.57 Million
1,306 Added 16.71%
9,120 $9.59 Million
Q2 2024

Aug 13, 2024

SELL
$883.2 - $1071.19 $28,262 - $34,278
-32 Reduced 0.41%
7,814 $8.21 Million
Q1 2024

May 14, 2024

SELL
$902.69 - $993.35 $1.94 Million - $2.14 Million
-2,153 Reduced 21.53%
7,846 $7.55 Million
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $2.77 Million - $3.15 Million
-3,571 Reduced 26.32%
9,999 $8.78 Million
Q3 2023

Nov 14, 2023

SELL
$692.45 - $844.37 $52.6 Million - $64.2 Million
-75,985 Reduced 84.85%
13,570 $11.2 Million
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $16.6 Million - $19.7 Million
-23,772 Reduced 20.98%
89,555 $64.3 Million
Q1 2023

May 17, 2023

SELL
$680.49 - $826.97 $35.9 Million - $43.7 Million
-52,791 Reduced 31.78%
113,327 $93.1 Million
Q4 2022

Feb 08, 2023

BUY
$705.89 - $766.39 $5.5 Million - $5.97 Million
7,793 Added 4.92%
166,118 $120 Million
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $20 Million - $25.3 Million
34,912 Added 28.29%
158,325 $109 Million
Q2 2022

Aug 16, 2022

BUY
$548.35 - $738.84 $56.4 Million - $76 Million
102,809 Added 498.98%
123,413 $73 Million
Q1 2022

May 13, 2022

SELL
$595.12 - $698.43 $19.3 Million - $22.6 Million
-32,380 Reduced 61.11%
20,604 $14.4 Million
Q4 2021

Feb 16, 2022

SELL
$543.48 - $670.97 $1.1 Million - $1.35 Million
-2,015 Reduced 3.66%
52,984 $33.5 Million
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $114,806 - $136,192
-200 Reduced 0.36%
54,999 $33.3 Million
Q2 2021

Aug 19, 2021

BUY
$472.8 - $558.54 $7.82 Million - $9.24 Million
16,546 Added 42.81%
55,199 $30.8 Million
Q1 2021

May 17, 2021

SELL
$446.73 - $548.2 $8.68 Million - $10.6 Million
-19,419 Reduced 33.44%
38,653 $18.3 Million
Q4 2020

Feb 16, 2021

BUY
$478.3 - $607.98 $6.7 Million - $8.52 Million
14,013 Added 31.81%
58,072 $28.1 Million
Q3 2020

Nov 10, 2020

SELL
$544.75 - $658.21 $563,816 - $681,247
-1,035 Reduced 2.3%
44,059 $24.7 Million
Q2 2020

Aug 12, 2020

BUY
$493.32 - $643.92 $20.4 Million - $26.7 Million
41,453 Added 1138.51%
45,094 $28.1 Million
Q4 2019

Feb 13, 2020

BUY
$274.13 - $376.51 $3,289 - $4,518
12 Added 0.33%
3,641 $1.37 Million
Q3 2019

Nov 14, 2019

BUY
$273.46 - $318.39 $26,799 - $31,202
98 Added 2.78%
3,629 $1.01 Million
Q2 2019

Aug 13, 2019

BUY
$299.6 - $414.82 $9,287 - $12,859
31 Added 0.89%
3,531 $1.11 Million
Q1 2019

May 14, 2019

BUY
$372.08 - $439.57 $44,277 - $52,308
119 Added 3.52%
3,500 $1.44 Million
Q4 2018

Feb 15, 2019

BUY
$335.82 - $403.04 $19,813 - $23,779
59 Added 1.78%
3,381 $1.26 Million
Q3 2018

Nov 15, 2018

BUY
$351.14 - $408.51 $25,984 - $30,229
74 Added 2.28%
3,322 $1.34 Million
Q2 2018

Aug 14, 2018

BUY
$284.6 - $344.99 $9,676 - $11,729
34 Added 1.06%
3,248 $1.12 Million
Q1 2018

May 08, 2018

BUY
$315.82 - $393.78 $26,844 - $33,471
85 Added 2.72%
3,214 $1.11 Million
Q4 2017

Feb 14, 2018

BUY
$358.63 - $469.95 $39,090 - $51,224
109 Added 3.61%
3,129 $1.18 Million
Q3 2017

Nov 14, 2017

BUY
$431.38 - $504.0 $1.3 Million - $1.52 Million
3,020
3,020 $1.35 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $73.4B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.